FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367184120> ?p ?o ?g. }

• W4367184120 abstract "Primary hemophagocytic lymphohistiocytosis (pHLH) is an inherited inflammatory syndrome driven by the exuberant activation of interferon-gamma (IFNg)-producing CD8 T cells. Towards this end, ruxolitinib treatment or IFNg neutralization (aIFNg) lessens immunopathology in a model of pHLH in which perforin-deficient mice (Prf1-/-) are infected with Lymphocytic Choriomeningitis virus (LCMV). However, neither agent completely eradicates inflammation. Two studies combining ruxolitinib with aIFNg report conflicting results with one demonstrating improvement and the other worsening of disease manifestations. As these studies used differing doses of drugs and varying LCMV strains, it remained unclear whether combination therapy is safe and effective.We previously showed that a ruxolitinib dose of 90 mg/kg lessens inflammation in Prf1-/- mice infected with LCMV-Armstrong. To determine whether this dose controls inflammation induced by a different LCMV strain, we administered ruxolitinib at 90mg/kg to Prf1-/- mice infected with LCMV-WE. To elucidate the impacts of single agent versus combination therapy, Prf1-/- animals were infected with LCMV, treated or not with ruxolitinib, aIFNg or both agents, and analyzed for disease features and the transcriptional impacts of therapy within purified CD8 T cells.Ruxolitinib is well-tolerated and controls disease regardless of the viral strain used. aIFNg, administered alone or with ruxolitinib, is most effective at reversing anemia and reducing serum IFNg levels. In contrast, ruxolitinib appears better than aIFNg, and equally or more effective than combination therapy, at lessening immune cell expansion and cytokine production. Each treatment targets distinct gene expression pathways with aIFNg downregulating IFNg, IFNa, and IL-6-STAT3 pathways, and ruxolitinib downregulating IL-6-STAT3, glycolysis, and reactive oxygen species pathways. Unexpectedly, combination therapy is associated with upregulation of genes driving cell survival and proliferation.Ruxolitinib is tolerated and curtails inflammation regardless of the inciting viral strain and whether it is given alone or in combination with aIFNg. When administered at the doses used in this study, the combination of ruxolitinb and aIFNg appears no better than treatment with either drug alone in lessening inflammation. Further studies are warranted to elucidate the optimal doses, schedules, and combinations of these agents for the treatment of patients with pHLH." @default.
• W4367184120 created "2023-04-28" @default.
• W4367184120 creator A5010615219 @default.
• W4367184120 creator A5013708643 @default.
• W4367184120 creator A5025442855 @default.
• W4367184120 creator A5029704780 @default.
• W4367184120 creator A5041988238 @default.
• W4367184120 creator A5052949902 @default.
• W4367184120 creator A5073328981 @default.
• W4367184120 date "2023-04-27" @default.
• W4367184120 modified "2023-09-27" @default.
• W4367184120 title "Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis" @default.
• W4367184120 cites W1937801816 @default.
• W4367184120 cites W1948341008 @default.
• W4367184120 cites W1966536060 @default.
• W4367184120 cites W1976702412 @default.
• W4367184120 cites W1983067071 @default.
• W4367184120 cites W1991241987 @default.
• W4367184120 cites W1997867127 @default.
• W4367184120 cites W2021028235 @default.
• W4367184120 cites W2042519375 @default.
• W4367184120 cites W2088801927 @default.
• W4367184120 cites W2091563075 @default.
• W4367184120 cites W2105957247 @default.
• W4367184120 cites W2130183546 @default.
• W4367184120 cites W2130410032 @default.
• W4367184120 cites W2137526110 @default.
• W4367184120 cites W2137850511 @default.
• W4367184120 cites W2144303909 @default.
• W4367184120 cites W2150631671 @default.
• W4367184120 cites W2153637944 @default.
• W4367184120 cites W2190766406 @default.
• W4367184120 cites W2210680772 @default.
• W4367184120 cites W2325441109 @default.
• W4367184120 cites W2328808092 @default.
• W4367184120 cites W2400154597 @default.
• W4367184120 cites W2462405760 @default.
• W4367184120 cites W2507807202 @default.
• W4367184120 cites W2605217619 @default.
• W4367184120 cites W2607349616 @default.
• W4367184120 cites W2746511594 @default.
• W4367184120 cites W2753024503 @default.
• W4367184120 cites W2770475298 @default.
• W4367184120 cites W2773048783 @default.
• W4367184120 cites W2937273212 @default.
• W4367184120 cites W2941779923 @default.
• W4367184120 cites W2969142409 @default.
• W4367184120 cites W2969697960 @default.
• W4367184120 cites W2973341403 @default.
• W4367184120 cites W3009581439 @default.
• W4367184120 cites W3021363743 @default.
• W4367184120 cites W3035147924 @default.
• W4367184120 cites W3047537798 @default.
• W4367184120 cites W3047986208 @default.
• W4367184120 cites W3112059656 @default.
• W4367184120 cites W3112658011 @default.
• W4367184120 cites W3126448789 @default.
• W4367184120 cites W3131959715 @default.
• W4367184120 cites W3138289408 @default.
• W4367184120 cites W3139833815 @default.
• W4367184120 cites W3179480983 @default.
• W4367184120 cites W3211858140 @default.
• W4367184120 cites W4200467105 @default.
• W4367184120 cites W4232835791 @default.
• W4367184120 cites W4283743523 @default.
• W4367184120 cites W4291227607 @default.
• W4367184120 cites W4305014652 @default.
• W4367184120 cites W4307552588 @default.
• W4367184120 cites W4312815231 @default.
• W4367184120 doi "https://doi.org/10.3389/fimmu.2023.1137037" @default.
• W4367184120 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37228616" @default.
• W4367184120 hasPublicationYear "2023" @default.
• W4367184120 type Work @default.
• W4367184120 citedByCount "0" @default.
• W4367184120 crossrefType "journal-article" @default.
• W4367184120 hasAuthorship W4367184120A5010615219 @default.
• W4367184120 hasAuthorship W4367184120A5013708643 @default.
• W4367184120 hasAuthorship W4367184120A5025442855 @default.
• W4367184120 hasAuthorship W4367184120A5029704780 @default.
• W4367184120 hasAuthorship W4367184120A5041988238 @default.
• W4367184120 hasAuthorship W4367184120A5052949902 @default.
• W4367184120 hasAuthorship W4367184120A5073328981 @default.
• W4367184120 hasBestOaLocation W43671841201 @default.
• W4367184120 hasConcept C167672396 @default.
• W4367184120 hasConcept C203014093 @default.
• W4367184120 hasConcept C2776112149 @default.
• W4367184120 hasConcept C2776914184 @default.
• W4367184120 hasConcept C2779574689 @default.
• W4367184120 hasConcept C2780007613 @default.
• W4367184120 hasConcept C2780076729 @default.
• W4367184120 hasConcept C2780190958 @default.
• W4367184120 hasConcept C71924100 @default.
• W4367184120 hasConcept C8891405 @default.
• W4367184120 hasConceptScore W4367184120C167672396 @default.
• W4367184120 hasConceptScore W4367184120C203014093 @default.
• W4367184120 hasConceptScore W4367184120C2776112149 @default.
• W4367184120 hasConceptScore W4367184120C2776914184 @default.
• W4367184120 hasConceptScore W4367184120C2779574689 @default.
• W4367184120 hasConceptScore W4367184120C2780007613 @default.
• W4367184120 hasConceptScore W4367184120C2780076729 @default.

• next